Abivax SA (ABVX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for ABVX, including 1 press release or news item. The most recent was published Nov 2, 2026.
ABVX rankings
Financial highlights
Full financials- Revenue, FY2025
- €4.57M
- Revenue growth
- -63.3%
- Net income, FY2025
- -€336.10M
- Net margin
- -7354.5%
- Free cash flow, FY2025
- -€161.27M
- Cash
- €516.68M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks35-75%
2026-05-102026-11-01
Mix690d
- Other4(67%)
- Offering1(17%)
- SEC Filings1(17%)
Latest news
25 items- PRAbivax to Participate in Upcoming Fall Investor ConferencesAbivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences: Guggenheim Healthcare Innovation ConferenceBoston, MassachusettsNovember 9-11, 2026Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET LifeSci Capital X Sofinnova Growth & Innovation SummitLondon, United KingdomNovember 16, 2026
- PRAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that seven scientific abstracts on obefazimod, its lead drug candidate for
- SECSEC Form F-6EF filed by Abivax SAF-6EF - Abivax S.A. (0001956827) (Subject)
- SECSEC Form 6-K filed by Abivax SA6-K - Abivax S.A. (0001956827) (Filer)
- PRAbivax Presents Business Updates and First Half 2026 Financial ResultsAbivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls ("CMC"), Quality and Information Technology ("IT") functionsCash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Abivax SASCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)
- PRAbivax Announces Positive Pre-NDA Interaction with the FDA for ObefazimodAbivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026 PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Adm
- PRAbivax Strengthens Commercial Capabilities With Strategic Leadership AppointmentsAbivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force development PARIS, France – July 23, 2026 – 10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the expansion of its Commercial Leadership Team with four strategic appointments spanning marketing, patient services, sales, comme
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Abivax SASCHEDULE 13D/A - Abivax S.A. (0001956827) (Subject)
- PRAbivax Announces Closing of $920 Million Public OfferingAbivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "Offering"), which includes the full exercise of t
- SECSEC Form 6-K filed by Abivax SA6-K - Abivax S.A. (0001956827) (Filer)
- SECSEC Form 424B5 filed by Abivax SA424B5 - Abivax S.A. (0001956827) (Filer)
- PRAbivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces that the underwriters of its offering of 6,400,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "
- SECSEC Form FWP filed by Abivax SAFWP - Abivax S.A. (0001956827) (Subject)
- PRCorrection: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesAbivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAPExpected gross proceeds of approximately $800M (€702M), before potential exercise of the Underwriters’ Option, are anticipated to extend the Company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development PARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing
- PRAbivax announces trading resumption of its ordinary shares on Euronext ParisAbivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted at the request of the Company on July 1, 2026 from 9:00 a.m. CEST in the context of the previously announced public offering by the Com
- PRAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAPExpected gross proceeds of approximately $800M (€702M), before potential exercise of the Underwriters’ Option, are anticipated to extend the Company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development PARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therap
- ANALYSTAbivax SA upgraded by Jefferies with a new price targetJefferies upgraded Abivax SA from Hold to Buy and set a new price target of $158.00
- PRAbivax announces temporary trading halt of its ordinary shares on Euronext ParisAbivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by th
- SECSEC Form FWP filed by Abivax SAFWP - Abivax S.A. (0001956827) (Subject)
- SECSEC Form 424B5 filed by Abivax SA424B5 - Abivax S.A. (0001956827) (Filer)
- PRAbivax Announces Launch of Public Offering of American Depositary SharesAbivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the launch of an underwritten public offering of approximately $600 million (approximately €527 million) of its American Depositary Shares ("ADSs"), each representing one ordinary share of Abivax, nominal value €0.01 per share (each, an "Ordinary Share"), in the United States (the "Offer
- SECSEC Form POSASR filed by Abivax SAPOSASR - Abivax S.A. (0001956827) (Filer)
- SECSEC Form 6-K filed by Abivax SA6-K - Abivax S.A. (0001956827) (Filer)
- PRAbivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety DatabaseAbivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis ("UC") population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatmentDose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease
ABVX FAQ
10 questionsWhat is the latest news on ABVX?
In the last 30 days Quantisnow tracked 1 wire item for ABVX: 1 press release or news item. The most recent was published on November 2, 2026.What is ABVX revenue?
Abivax SA (ABVX) reported €4.57M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 63.3% from the year before.Is ABVX profitable?
No. Abivax SA reported a net loss of €336.10M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ABVX have?
Abivax SA reported €516.68M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ABVX stock trade?
Abivax SA (ABVX) is listed on NASDAQ.What sector and industry is ABVX in?
Abivax SA operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Abivax SA go public?
Abivax SA (ABVX) completed its IPO in 2023.What are analysts saying about ABVX?
Across the last 8 analyst actions on Abivax SA, there were 2 upgrades and 1 downgrade. The most recent action was from Jefferies: Buy with a $158.00 price target on 2026-07-01. Recent price targets range from $90.00 to $176.00.What companies are similar to ABVX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABVX side-by-side with any of them on Quantisnow.How can I track ABVX on Quantisnow?
Quantisnow aggregates Abivax SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABVX to receive live email and push alerts on every new disclosure.